151 related articles for article (PubMed ID: 23644715)
1. The vanadyl chelate bis(acetylacetonato)oxovanadium(IV) increases the fractional uptake of 2-(fluorine-18)-2-deoxy-D-glucose by cultured human breast carcinoma cells.
Makinen MW; Bamba R; Ikejimba L; Wietholt C; Chen CT; Conzen SD
Dalton Trans; 2013 Sep; 42(33):11862-7. PubMed ID: 23644715
[TBL] [Abstract][Full Text] [Related]
2. Structural origins of the insulin-mimetic activity of bis(acetylacetonato)oxovanadium(IV).
Makinen MW; Brady MJ
J Biol Chem; 2002 Apr; 277(14):12215-20. PubMed ID: 11815612
[TBL] [Abstract][Full Text] [Related]
3. The vanadyl (VO2+) chelate bis(acetylacetonato)oxovanadium(IV) potentiates tyrosine phosphorylation of the insulin receptor.
Ou H; Yan L; Mustafi D; Makinen MW; Brady MJ
J Biol Inorg Chem; 2005 Dec; 10(8):874-86. PubMed ID: 16235045
[TBL] [Abstract][Full Text] [Related]
4. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
5. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II.
Ong LC; Jin Y; Song IC; Yu S; Zhang K; Chow PK
Acta Radiol; 2008 Dec; 49(10):1145-53. PubMed ID: 18979289
[TBL] [Abstract][Full Text] [Related]
6. New vanadium-based magnetic resonance imaging probes: clinical potential for early detection of cancer.
Mustafi D; Peng B; Foxley S; Makinen MW; Karczmar GS; Zamora M; Ejnik J; Martin H
J Biol Inorg Chem; 2009 Nov; 14(8):1187-97. PubMed ID: 19572156
[TBL] [Abstract][Full Text] [Related]
7. 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers.
Palaskas N; Larson SM; Schultz N; Komisopoulou E; Wong J; Rohle D; Campos C; Yannuzzi N; Osborne JR; Linkov I; Kastenhuber ER; Taschereau R; Plaisier SB; Tran C; Heguy A; Wu H; Sander C; Phelps ME; Brennan C; Port E; Huse JT; Graeber TG; Mellinghoff IK
Cancer Res; 2011 Aug; 71(15):5164-74. PubMed ID: 21646475
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice.
McLarty K; Moran MD; Scollard DA; Chan C; Sabha N; Mukherjee J; Guha A; McLaurin J; Nitz M; Houle S; Wilson AA; Reilly RM; Vasdev N
Nucl Med Biol; 2011 Oct; 38(7):953-9. PubMed ID: 21982567
[TBL] [Abstract][Full Text] [Related]
9. Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer.
von Forstner C; Egberts JH; Ammerpohl O; Niedzielska D; Buchert R; Mikecz P; Schumacher U; Peldschus K; Adam G; Pilarsky C; Grutzmann R; Kalthoff H; Henze E; Brenner W
J Nucl Med; 2008 Aug; 49(8):1362-70. PubMed ID: 18632830
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic activation of tumor hypoxia: a means to increase tumor 2-deoxy-2-[18F]fluoro-D-glucose uptake?
Mees G; Dierckx R; Vangestel C; Laukens D; Van Damme N; Van de Wiele C
Mol Imaging; 2013; 12(1):49-58. PubMed ID: 23348791
[TBL] [Abstract][Full Text] [Related]
13. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.
Maynard J; Ricketts SA; Gendrin C; Dudley P; Davies BR
Mol Imaging Biol; 2013 Aug; 15(4):476-85. PubMed ID: 23344784
[TBL] [Abstract][Full Text] [Related]
14. The effect of PPAR-γ agonist on (18)F-FDG PET imaging for differentiating tumors and inflammation lesions.
Cheong SJ; Lee CM; Kim EM; Lim ST; Sohn MH; Jeong HJ
Nucl Med Biol; 2015 Feb; 42(2):85-91. PubMed ID: 25441255
[TBL] [Abstract][Full Text] [Related]
15. Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer.
Wuest M; Trayner BJ; Grant TN; Jans HS; Mercer JR; Murray D; West FG; McEwan AJ; Wuest F; Cheeseman CI
Nucl Med Biol; 2011 May; 38(4):461-75. PubMed ID: 21531283
[TBL] [Abstract][Full Text] [Related]
16. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
[TBL] [Abstract][Full Text] [Related]
17. 2-fluoro-2-deoxy-D-glucose positron emission tomography versus conventional imaging for the diagnosis of breast cancer and lymph node metastases.
Shao M; Zi J; Wen G
J Cancer Res Ther; 2018 Sep; 14(Supplement):S661-S666. PubMed ID: 30249884
[TBL] [Abstract][Full Text] [Related]
18. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology?
Basu S; Mavi A; Cermik T; Houseni M; Alavi A
Mol Imaging Biol; 2008; 10(1):62-6. PubMed ID: 18000713
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression.
Yamada A; Oguchi K; Fukushima M; Imai Y; Kadoya M
Ann Nucl Med; 2006 Nov; 20(9):597-604. PubMed ID: 17294670
[TBL] [Abstract][Full Text] [Related]
20. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.
Avril N; Menzel M; Dose J; Schelling M; Weber W; Jänicke F; Nathrath W; Schwaiger M
J Nucl Med; 2001 Jan; 42(1):9-16. PubMed ID: 11197987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
